During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
|Articles|February 24, 2015
- NSCLC (Issue 6)
- Volume 6
- Issue 1
Maintenance Therapies for Patients with Non-Small Cell Lung Cancer
Author(s)Benjamin P. Levy, MD
Benjamin P. Levy, MD, director of thoracic medical oncology, Mount Sinai Health System, discusses maintenance therapies for patients with non-small cell lung cancer.
Advertisement
Benjamin P. Levy, MD, assistant professor of medicine, Icahn School of Medicine at Mount Sinai, director of thoracic medical oncology, Mount Sinai Health System, discusses maintenance therapies for patients with non-small cell lung cancer.
<<<
Articles in this issue
over 11 years ago
Nanovesicles as Targeted Therapy for Lung Cancerover 11 years ago
Prior Cancer Diagnosis Not Viable Exclusion From Lung Cancer Trialsover 11 years ago
Liquid Biopsy Use in NSCLC Clinical Practice on the Horizonover 11 years ago
Lung Cancer Screening: Implementing the New Protocolover 11 years ago
Challenges Oncologists Face in Treating Lung Cancerover 11 years ago
Diagnostic Platforms for Lung Cancerover 11 years ago
Potential Modulator of NSCLC Metastasis IdentifiedAdvertisement
Related to this article
The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5